Boston Scientific gains FDA nod for drug-coated coronary balloon
BTIG analyst Marie Thibault said physicians could rapidly adopt the first-of-its-kind device.
Boston Scientific gains FDA nod for drug-coated coronary balloon Read More »
Uncategorized
Medtronic asks ITC to stop sales, imports of Axonics devices
The complaint is the latest move in a long-running patent fight between the two companies regarding neuromodulation devices.
Medtronic asks ITC to stop sales, imports of Axonics devices Read More »
Ironwood Nabs Phase III Win, Still Sees Stock Nosedive
Despite Ironwood Pharmaceuticals’ apraglutide getting positive late-stage study results in treating short bowel syndrome with intestinal failure, the stock plummeted nearly 40% on Thursday.
Ironwood Nabs Phase III Win, Still Sees Stock Nosedive Read More »
Walgreens’ VillageMD to exit Illinois
The primary care chain will shutter its remaining clinics in the state on April 19, marking the latest closures as Walgreens cuts costs.
Rare Disease Day Reminds Biopharma of Opportunities, Challenges
The annual observance highlights how far the industry has come and serves as a wake-up call for how far it must still go to meet the needs of patients with rare diseases.
Rare Disease Day Reminds Biopharma of Opportunities, Challenges Read More »
Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon
Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB).
Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon Read More »
NMPA Approves the NDA for CARsgen’s BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
CARsgen Therapeutics Holdings Limited announces that today the National Medical Products Administration (“NMPA”) of China has approved the New Drug Application (“NDA”) for zevorcabtagene autoleucel.
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
Mallinckrodt plc, a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Mallinckrodt’s supplemental New Drug Application (sNDA) for the Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector.
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
Biodesix, Inc. provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023.
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights Read More »
Una trayectoria de innovación y crecimiento
La plataforma de pagos bill_line ha dejado una marca indeleble en el mundo de la tecnología financiera con su celebración del cuarto aniversario el año pasado. En esta revisión detallada, exploraremos los hitos más significativos alcanzados por bill_line en el tran …